2021.Oct.13
OBI filed an Application of Phase II human clinical trial for Globo-H Antibody Drug Conjugate, OBI-999, to TFDA
1. Date of occurrence of the event: October 13, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding ratios: Not applicable 5. Cause of occurrence: OBI filed the application of Phase II human clinical trial for Globo-H Antibody Drug Conjugate (ADC), […]
This article is password protected.
To view the content, please enter your password in the field below